Roberto Rodriguez-Roisin
University of Barcelona
Internal medicineSurgeryPathologyCardiologyIntensive care medicinePhysical therapyPlaceboAsthmaRespiratory diseaseSalmeterolCOPDExacerbationObstructive lung diseaseLungDiseaseSpirometryLamaPopulationPulmonary diseaseSeverity of illnessAnesthesiaRespiratory systemMedicine
127Publications
37H-index
24.2kCitations
Publications 116
Newest
#1Nuria MendozaH-Index: 1
#2Eva RivasH-Index: 9
Last. Rosa FanerH-Index: 25
view all 7 authors...
The hepatopulmonary syndrome (HPS) is defined by the presence of pulmonary gas exchange abnormalities due to intrapulmonary vascular dilatations in patients with chronic liver disease. Changes in DNA methylation reflect the genomic variation. Since liver transplant (LT) reverts HPS we hypothesized that it may be associated with specific liver epigenetic changes. Thus, the aim of this study was to investigate the role of the liver epigenome in patients with HPS. We extracted DNA from paraffin emb...
Source
#1Carlos A. Torres-Duque (Universidad de La Sabana)H-Index: 14
#2Alejandro Casas (Del Rosario University)H-Index: 51
Last. Roberto Rodriguez-Roisin (University of Barcelona)H-Index: 37
view all 6 authors...
4 CitationsSource
#1Claus Vogelmeier (University of Marburg)H-Index: 70
Last. Gary T. FergusonH-Index: 38
view all 6 authors...
Abstract Chronic obstructive pulmonary disease (COPD) is currently a leading cause of death worldwide, and its burden is expected to rise in the coming years. Common COPD symptoms include dyspnea, cough and/or sputum production. Some patients may experience acute worsening of symptoms (known as an exacerbation), and therefore require additional therapy. Exacerbations are mainly triggered by respiratory infections and environmental factors. Healthcare professionals face many challenges in COPD ma...
17 CitationsSource
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) progression is variable and affects several disease domains, including decline in lung function, exercise capacity, muscle strength, and health status as well as changes in body composition. We aimed to assess the longitudinal association of physical activity (PA) with these a priori selected components of disease progression. METHODS: We studied 114 COPD patients from the PAC-COPD cohort (94% male, mean [SD], 70 yr [8 yr] of age, 54 [16...
10 CitationsSource
#1Roberto Rodriguez-Roisin (University of Barcelona)H-Index: 37
#2Bartolome R. Celli (Brigham and Women's Hospital)H-Index: 127
Source
#1Gerard J. Criner (TU: Temple University)H-Index: 84
#2Fernando J. Martinez (NewYork–Presbyterian Hospital)H-Index: 148
Last. Bartolome R. Celli (Brigham and Women's Hospital)H-Index: 127
view all 31 authors...
8 CitationsSource
#1Henrik WatzH-Index: 35
#2Kay Tetzlaff (University of Tübingen)H-Index: 24
Last. Peter M.A. CalverleyH-Index: 84
view all 8 authors...
Background Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with loss of lung function and poor outcomes for patients. However, there are limited data on the time course of changes in forced expiratory volume in 1 s (FEV1) preceding the first reported symptom and after the start of an exacerbation.
10 CitationsSource
1 Citations
#1Alberto Papi (University of Ferrara)H-Index: 92
#2Dermot Ryan (Edin.: University of Edinburgh)H-Index: 53
Last. David Price (Aberd.: University of Aberdeen)H-Index: 160
view all 12 authors...
Abstract Background Patients with asthma and elevated blood eosinophils are at increased risk of severe exacerbations. Management of these patients should consider non-adherence to inhaled corticosteroid (ICS) therapy as a factor for increased exacerbation risk. Objective To investigate whether poor adherence to ICS therapy explains the occurrence of asthma exacerbations in patients with elevated blood eosinophil levels. Methods This historical cohort study identified patients within the Optimum...
28 CitationsSource
#1Henrik WatzH-Index: 35
#2Helgo MagnussenH-Index: 68
Last. Claus Vogelmeier (University of Marburg)H-Index: 70
view all 7 authors...
Introduction: The 2017 GOLD* A–D grouping scheme is solely based on exacerbation history and symptoms, and no longer considers lung function. Aim: To examine the effect of ICS withdrawal in the WISDOM trial within the new GOLD 2017 groups A–D. Methods: In WISDOM, a 12-month, double-blind, parallel-group study, patients with COPD who had ≥1 exacerbation in the preceding 12 months and FEV1 Results: The proportion of the total population of patients experiencing exacerbations was lowest in the GOLD...
Source